Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Toxicogenomics and Classic Toxicology: How to Improve Prediction and Mechanistic Understanding of Human Toxicity

  • Protocol
Essential Concepts in Toxicogenomics

Part of the book series: Methods in Molecular Biology™ ((MIMB,volume 460))

Summary

The field of toxicogenomics has been advancing during the past decade or so since its origin. Most pharmaceutical companies are using it in one or more ways to improve their productivity and supplement their classic toxicology studies. Acceptance of toxicogenomics will continue to grow as regulatory concerns are addressed, proof of concept studies are disseminated more fully, and internal case studies show value for the use of this new technology in concert with classic testing.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kola, I. and Landis, J. (2004) Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711–715.

    Article  CAS  PubMed  Google Scholar 

  2. Mayne, J.T., Ku, W.W., and Kennedy, S.P. (2006) Informed toxicity assessment in drug discovery: systems-based toxicology. Curr. Opin. Drug Discov. Dev. 9, 75–83.

    CAS  Google Scholar 

  3. Barros, S.A. (2005) The importance of applying toxicogenomics to increase the efficiency of drug discovery. Pharmacogenomics 6, 547–550.

    Article  PubMed  Google Scholar 

  4. DiMasi, J.A., Hansen, R.W., and Grabowski, H.G. (2003) The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151–185.

    Article  PubMed  Google Scholar 

  5. Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., et al. (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56–67.

    Article  CAS  PubMed  Google Scholar 

  6. Suter, L., Babiss, L.E., and Wheeldon, E.B. (2004) Toxicogenomics in predictive toxicology in drug development. Chem. Biol. 11, 161–171.

    CAS  PubMed  Google Scholar 

  7. DiMasi, J.A. (2002) The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics 20 (Suppl 3), 1–10.

    Article  PubMed  Google Scholar 

  8. Boverhof, D.R. and Zacharewski, T.R. (2006) Toxicogenomics in risk assessment: applications and needs. Toxicol. Sci. 89, 352–360.

    Article  CAS  PubMed  Google Scholar 

  9. Yang, Y., Blomme, E.A., and Waring, J.F. (2004) Toxicogenomics in drug discovery: from preclinical studies to clinical trials. Chem. Biol. Interact. 150, 71–85.

    Article  CAS  PubMed  Google Scholar 

  10. Luhe, A., Suter, L., Ruepp, S., Singer, T., Weiser, T., and Albertini, S. (2005) Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit? Mutat. Res. 575, 102–115.

    PubMed  Google Scholar 

  11. Lord, P.G. (2004) Progress in applying genomics in drug development. Toxicol. Lett. 149, 371–375.

    Article  CAS  PubMed  Google Scholar 

  12. Searfoss, G.H., Ryan, T.P., and Jolly, R.A. (2005) The role of transcriptome analysis in pre-clinical toxicology. Curr. Mol. Med. 5, 53–64.

    Article  CAS  PubMed  Google Scholar 

  13. Guerreiro, N., Staedtler, F., Grenet, O., Kehren, J., and Chibout, S.D. (2003) Toxicogenomics in drug development. Toxicol. Pathol. 31, 471–479.

    CAS  PubMed  Google Scholar 

  14. Dix, D.J., Houck, K.A., Martin, M.T., Richard, A.M., Setzer, R.W., and Kavlock, R.J. (2007) The ToxCast Program for Prioritizing Toxicity Testing of Environmental Chemicals. Toxicol. Sci. 95, 5–12.

    Article  CAS  PubMed  Google Scholar 

  15. Lord, P.G., Nie, A., and McMillian, M. (2006) Application of genomics in preclinical drug safety evaluation. Basic Clin. Pharmacol. Toxicol. 98, 537–546.

    Article  CAS  PubMed  Google Scholar 

  16. Shioda, T., Chesnes, J., Coser, K.R., Zou, L., Hur, J., Dean, K.L., et al. (2006) Importance of dosage standardization for interpreting transcriptomal signature profiles: evidence from studies of xenoestrogens. Proc. Natl. Acad. Sci. U. S. A. 103, 12033–12038.

    Article  CAS  PubMed  Google Scholar 

  17. Farr, S. and Dunn, R.T. II (1999) Concise review: gene expression applied to toxicology. Toxicol. Sci. 50, 1–9.

    Article  CAS  PubMed  Google Scholar 

  18. Heinloth, A.N., Irwin, R.D., Boorman, G.A., Nettesheim, P., Fannin, R.D., Sieber, S.O., et al. (2004) Gene expression profiling of rat livers reveals indicators of potential adverse effects. Toxicol. Sci. 80, 193–202.

    Article  CAS  PubMed  Google Scholar 

  19. Nie, A.Y., McMillian, M., Brandon, P.J., Leone, A., Bryant, S., Yieh, L., et al. (2006) Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol. Carcinog. 45, 914–933.

    Article  CAS  PubMed  Google Scholar 

  20. Mattes, W.B., Daniels, K.K., Summan, M., Xu, Z.A., and Mendrick, D.L. (2006) Tissue and species distribution of the glutathione pathway transcriptome. Xenobiotica 36, 1081–1121.

    Article  CAS  PubMed  Google Scholar 

  21. Martin, R., Rose, D., Yu, K., and Barros, S. (2006) Toxicogenomics strategies for predicting drug toxicity. Pharmacogenomics 7, 1003–1016.

    Article  CAS  PubMed  Google Scholar 

  22. Hultin-Rosenberg, L., Jagannathan, S., Nilsson, K.C., Matis, S.A., Sjogren, N., Huby, R.D., et al. (2006) Predictive models of hepatotoxicity using gene expression data from primary rat hepatocytes. Xenobiotica 36, 1122–1139.

    Article  CAS  PubMed  Google Scholar 

  23. Kaplowitz, N. (2005) Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4, 489–499.

    Article  CAS  PubMed  Google Scholar 

  24. Dieckhaus, C.M., Miller, T.A., Sofia, R.D., and Macdonald, T.L. (2000) A mechanistic approach to understanding species differences in felbamate bioactivation: relevance to drug-induced idiosyncratic reactions. Drug Metab. Dispos. 28, 814–822.

    Google Scholar 

  25. Alden, C., Lin, J., and Smith, P. (2003) Predicting toxicology technology for avoiding idiosyncratic liver injury. Preclinica May/June, 27–35.

    Google Scholar 

  26. Popovic, M., Nierkens, S., Pieters, R., and Uetrecht, J. (2004) Investigating the role of 2-phenylpropenal in felbamate-induced idiosyncratic drug reactions. Chem. Res. Toxicol. 17, 1568–1576.

    Article  CAS  PubMed  Google Scholar 

  27. Ettinger, A.B., Jandorf, L., Berdia, A., Andriola, M.R., Krupp, L.B., and Weisbrot, D.M. (1996) Felbamate-induced headache. Epilepsia 37, 503–505.

    Article  CAS  PubMed  Google Scholar 

  28. McGee, J.H., Erikson, D.J., Galbreath, C., Willigan, D.A., and Sofia, R.D. (1998) Acute, subchronic, and chronic toxicity studies with felbamate, 2-phenyl-1.,3-propanediol dicarbamate. Toxicol. Sci. 45, 225–232.

    Article  CAS  PubMed  Google Scholar 

  29. Carvajal Garcia-Pando, A., Garcia, d.P., Sanchez, A.S., Velasco, M.A., Rueda de Castro, A.M., and Lucena, M.I. (2002) Hepatotoxicity associated with the new antidepressants. J. Clin. Psychiatry 63, 135–137.

    PubMed  Google Scholar 

  30. Stewart, D.E. (2002) Hepatic adverse reactions associated with nefazodone. Can. J. Psychiatry 47, 375–377.

    PubMed  Google Scholar 

  31. Choi, S. (2003) Nefazodone (Serzone) withdrawn because of hepatotoxicity. CMAJ. 169, 1187.

    PubMed  Google Scholar 

  32. Aranda-Michel, J., Koehler, A., Bejarano, P.A., Poulos, J.E., Luxon, B.A., Khan, C.M., et al. (1999) Nefazodone-induced liver failure: report of three cases. Ann. Intern. Med. 130, 285–288.

    CAS  PubMed  Google Scholar 

  33. Schrader, G.D. and Roberts-Thompson, I.C. (1999) Adverse effect of nefazodone: hepatitis. Med. J. Aust. 170, 452.

    CAS  PubMed  Google Scholar 

  34. Kostrubsky, S.E., Strom, S.C., Kalgutkar, A.S., Kulkarni, S., Atherton, J., Mireles, R., et al. (2006) Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol. Sci. 90, 451–459.

    Article  CAS  PubMed  Google Scholar 

  35. Greene, D.S. and Barbhaiya, R.H. (1997) Clinical pharmacokinetics of nefazodone. Clin. Pharmacokinet. 33, 260–275.

    Article  CAS  PubMed  Google Scholar 

  36. DeVane, C.L., Donovan, J.L., Liston, H.L., Markowitz, J.S., Cheng, K.T., Risch, S.C., and Willard, L. (2004) Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J. Clin. Psychopharmacol. 24, 4–10.

    Article  CAS  PubMed  Google Scholar 

  37. Kalgutkar, A.S., Vaz, A.D., Lame, M.E., Henne, K.R., Soglia, J., Zhao, S.X., et al. (2005) Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab. Dispos. 33, 243–253.

    Article  CAS  PubMed  Google Scholar 

  38. Kostrubsky, V.E., Strom, S.C., Hanson, J., Urda, E., Rose, K., Burliegh, J., et al. (2003) Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. Toxicol. Sci. 76, 220–228.

    Article  CAS  PubMed  Google Scholar 

  39. Landis, G.N. and Tower, J. (2005) Superoxide dismutase evolution and life span regulation. Mech. Ageing Dev. 126, 365–379.

    Article  CAS  PubMed  Google Scholar 

  40. Dambach, D.M., Andrews, B.A., and Moulin, F. (2005) New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicol. Pathol. 33, 17–26.

    Article  CAS  PubMed  Google Scholar 

  41. Meador, V., Jordan, W., and Zimmermann, J. (2002) Increasing throughput in lead optimization in vivo toxicity screens. Curr. Opin. Drug Discov. Dev. 5, 72–78.

    CAS  Google Scholar 

  42. Liguori, M.J., Anderson, L.M., Bukofzer, S., McKim, J., Pregenzer, J.F., Retief, J., et al. (2005) Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Hepatology 41, 177–186.

    Article  CAS  PubMed  Google Scholar 

  43. Waring, J.F., Ciurlionis, R., Jolly, R.A., Heindel, M., and Ulrich, R.G. (2001) Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol. Lett. 120, 359–368.

    Article  CAS  PubMed  Google Scholar 

  44. Sawada, H., Takami, K., and Asahi, S. (2005) A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol. Sci. 83, 282–292.

    Article  CAS  PubMed  Google Scholar 

  45. Reynolds, V.L. (2005) Applications of emerging technologies in toxicology and safety assessment. Int. J. Toxicol. 24, 135–137.

    Article  PubMed  Google Scholar 

  46. Shi, L., Reid, L.H., Jones, W.D., Shippy, R., Warrington, J.A., Baker, S.C., et al. (2006) The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol. 24, 1151–1161.

    Article  CAS  PubMed  Google Scholar 

  47. Canales, R.D., Luo, Y., Willey, J.C., Austermiller, B., Barbacioru, C.C., Boysen, C., et al. (2006) Evaluation of DNA microarray results with quantitative gene expression platforms. Nat. Biotechnol. 24, 1115–1122.

    Article  CAS  PubMed  Google Scholar 

  48. Guo, L., Lobenhofer, E.K., Wang, C., Shippy, R., Harris, S.C., Zhang, L., et al. (2006) Rat toxicogenomic study reveals analytical consistency across microarray platforms. Nat. Biotechnol. 24, 1162–1169.

    Article  CAS  PubMed  Google Scholar 

  49. Goodsaid, F. and Frueh, F. (2006) Process map proposal for the validation of genomic biomarkers. Pharmacogenomics 7, 773–782.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Toxicogenomics, Gene Logic Inc., Gaithersburg, Maryland

    Donna L. Mendrick

Authors
  1. Donna L. Mendrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Gene Logic Inc, Gaithersburg, MD, USA

    Donna L. Mendrick

  2. The Critical Path Institute, Rockville, MD, USA

    William B. Mattes

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Mendrick, D.L. (2008). Toxicogenomics and Classic Toxicology: How to Improve Prediction and Mechanistic Understanding of Human Toxicity. In: Mendrick, D.L., Mattes, W.B. (eds) Essential Concepts in Toxicogenomics. Methods in Molecular Biology™, vol 460. Humana Press. https://doi.org/10.1007/978-1-60327-048-9_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-048-9_1

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-638-2

  • Online ISBN: 978-1-60327-048-9

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation